Journal article
Efficacy and Safety of 177Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
L Zidan, A Iravani, K Oleinikov, S Ben-Haim, DJ Gross, A Meirovitz, O Maimon, T Akhurst, M Michael, RJ Hicks, S Grozinsky-Glasberg, G Kong
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2022
Abstract
The purpose of this study was to assess the efficacy and safety of 177Lu-DOTATATE in patients with somatostatin receptor (SSR)-positive lung neuroendocrine tumors (NETs). Methods: This is a retrospective review of the outcome of patients with typical carcinoid (TC) and atypical carcinoid (AC), treated with 177Lu-DOTATATE at 2 ENETS Centers of Excellence. Morphologic imaging (RECIST 1.1) and 68Ga-DOTATATE PET/CT responses were assessed at 3 mo after completion of 177Lu-DOTATATE. Concordance between 2 response assessment methods was evaluated by k statistics. Progression-free survival (PFS) and overall survival (OS) were estimated by Kaplan-Meier analysis and compared by Log-rank test. Treatme..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Grace Kong is supported by a Clinical Fellowship Award from the Peter MacCallum Foundation. Rodney J. Hicks is recipient of a National Health and Medical Research Council Practitioner Fellowship (APP1108050). No other potential conflict of interest relevant to this article was reported.